He then completed his internship and residency in internal medicine at the Massachusetts General Hospital and his fellowship training in medical oncology at the Dana–Farber Cancer Institute.
[5] At Broad Institute, Garraway's research involved the systematic characterization of critical and targetable mechanisms enacted by common genomic alterations in human tumors.
His research team was among the first to adapt genomics technologies to enable scalable, high-throughput clinical approaches to cancer gene mutation profiling.
[11] On September 14, 2016, Garraway was appointed the Senior Vice President of Global Oncology at Eli Lilly and Company, succeeding Richard Gaynor.
[5] As of 2007[update], his younger sister Isla is a urologist and surgeon at University of California, Los Angeles's Jonsson Comprehensive Cancer Center.